Care needed in interpretation of cancer survival measures
Cancer patient survival obtained from population-based cancer studies is the optimum method to monitor and assess the eff ectiveness of patient care.
1 Consideration of these estimates in conjunction with estimates of cancer incidence and mortality is still important. 2 As a result, there is much interest in the assessment of progress in terms of cancer survival. 3, 4 Quantifi cation of the improvements in cancer patient survival because of successes in some areas, such as treatment, diagnostic techniques, and awareness or screening campaigns, is of paramount importance to health-care offi cials, health policy makers, and charities supporting these developments in cancer control. However, to make a fair comparison-to compare like with like-is essential to assess progress accurately.
In Relative survival compares the survival in patients with cancer to a relevant cohort without cancer, and is important to account for the changing risk of dying of something else. Under specifi c assumptions, 6 average relative survival estimates marginal net survival, which is completely independent of other-cause mortality. The standardisation to 1996-99 neatly overcomes the other issues of comparability (age and cancer distributions), but comes at the cost of the inability to interpret the measures. Measures that are optimum for comparability cannot be easily interpreted in terms of the survival experience of individuals, and vice versa.
The authors note that the fi gures they report are readily interpreted incorrectly. 7, 8 The survival index for all cancers combined is something of a holy grail for headline writers, because it gives one summary fi gure to show progress in cancer as a whole over time. However, similarly to all averages and summaries, important detail lies behind the number. The survival index (and the site-specifi c estimates) measure net survival, which adds substantially to the diffi culty in interpretation, but that subtlety is often missed. The all-cancer survival index of 50% at 10 years might be interpreted as meaning that 50% of cancer patients will survive for 10 years or more, which is wrongas the authors discuss 5 -but it is worth stressing this point. The problem relates to the three main Derived from an England and Wales life table. Columns 2 and 3 give the actual probabilities of death due to the disease and due to other causes, and sum to the value given in column 4 (the overall probability of death). The fi rst column gives a net measure and has no interpretation as the actual probability of death due to cancer. adjustments necessary for making the index possible to compare across time. The measure is independent of competing mortality because of other causes that also heavily aff ect patients with cancer; for most sites, the diagnosed patients are of an older age. I show an example in which the relative survival estimate at 10 years is 50% at every age. England and Wales population mortality data are used to convert these estimates 9, 10 into the 10 year all-cause probability of death (table) . An 80-year-old has a 16% chance of being alive at 10 years, despite the net estimate of 50%. For younger patients, the diff erences are smaller, but still exist. Overall, fewer patients with cancer will be alive 10 years after diagnosis if we use all-cause death as the outcome, rather than a net measure. Diffi culties are also introduced by standardisation; patients with cancer diagnosed now (and in the future) might be older on average, and have a higher proportion of cancers with a better or worse prognosis than in 1996-99. The survival index is being standardised to a population that might not be a good representation of the present population structure, making present and future interpretability of the measure more diffi cult. Additionally, any biases in site-specifi c estimates will also contribute to the survival index.
Quaresma and colleagues mainly concentrate on age-standardised measures. However, the age-group specifi c estimates need to be examined across each site to understand fully whether improvements in outcomes occur across all ages simultaneously, which is unlikely to be the case. For instance, certain treatment improvements will be seen only for younger patients. Although the overall measures reported as headline fi gures are important, understanding of the reasons for the changes over time is even more important. Quaresma and colleagues fi t very sophisticated models to arrive at the values that they present. A lot of extra information can be garnered from these models. Metrics that underline in which subgroups of patients and at what point in follow-up improvements have occurred should be further used. 11, 12 Overall, Quaresma and colleagues should be congratulated on a carefully constructed method for comparisons across time. This is a useful epidemiological measure for quantifi cation of overall improvements in cancer survival. The site-specifi c indices are particularly useful to understand whether progress has been made and when in calendar time we observe the improvement. However, caution should be used when interpreting the fi gures themselves. I would encourage the continued development of statistical approaches that help to pinpoint the reasons for these overall improvements. I would also further stress that other statistical metrics, which are more readily interpretable for patients and health-care professionals, should be used. 12 
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